MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2018 International Congress

    Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

    J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

    Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…
  • 2018 International Congress

    Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

    Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…
  • 2018 International Congress

    The course of Parkinson’s disease in patients with impaired carbohydrate metabolism

    F. Akhmedova, B. Shagazatova, D. Artikova, F. Mirxaydarova (Tashkent, Uzbekistan)

    Objective: To study the state of lipid metabolism in PD patients with concomitant type 2diabetes (with different glucose tolerance and the effect of DA agonist…
  • 2018 International Congress

    Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…
  • 2018 International Congress

    Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

    S. V G, P. Vavia (Mumbai, India)

    Objective: The objective of this research work is to develop a lipid nanocarrier system of Bromocriptine and evaluate its increased efficacy in the management of…
  • 2018 International Congress

    Dopaminergic medication changes affect cognitive, mood, and quality of life outcomes after STN DBS

    D. Floden, O. Hogue, M. Saupe, R. Busch, K. Wilson, A. Ahmed (Cleveland, OH, USA)

    Objective: To determine whether there is a relationship between dopaminergic medication reduction and cognitive, mood, or quality of life outcomes after STN DBS for PD.…
  • 2018 International Congress

    The impact of a wearable device on Parkinson’s disease motor symptom management in patients starting rotigotine transdermal patch

    S. Isaacson, B. Boroojerdi, K. Klos, S. Carson, M. Markowitz, D. Heldman, M. Phillips, D. Terricabras, F. Woltering, D. Truong (Boca Raton, FL, USA)

    Objective: Open-label, multi-center pilot study (PD0049) to evaluate the impact of Kinesia 360 (an “at home” wearable device) on motor symptom management in Parkinson’s disease…
  • 2018 International Congress

    EEG microstates changes in response to increase in dopaminergic stimulation in treated typical Parkinson’s disease patients without clinical fluctuations

    V. Cortés, I. Serrano, N. Mendes, M. Del Castillo, A. Arroyo, J. Andreo, M. Del Valle, J. Herreros, JP. Romero, (Madrid, Spain)

    Objective: Neurotropic drugs may modulate Electroencephalography (EEG) microstates (MS), but there are no works showing EEG MS default-mode network changes in response to dopaminergic stimulation…
  • 2017 International Congress

    Genetic susceptibility associated to impulse control disorders and compulsive behaviors in Parkinson’s disease from a Spanish population.

    S. JESUS, C. TEJERA-PARRADO, C. CORTES, M. BONILLA-TORIBIO, I. BERNAL-BERNAL, M. LABRADOR, L. VARGAS-GONZÁLEZ, M. BERNAL, A. ADARMES, F. CARRILLO, M. CARBALLO, P. GÓMEZ-GARRE, P. MIR (SEVILLA, Spain)

    Objective: Our aim was to identify if there is any difference in the genetic variants linked to an increased susceptibility to suffer impulse control disorders…
  • 2017 International Congress

    Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients

    D. Woitalla, M. Asgharnejad, L. Joeres, J.-C. Schuller, K.R. Chaudhuri (Bochum, Germany)

    Objective: Prospective non-interventional study conducted in routine clinical practice (PD0013; NCT02227355) to compare effectiveness and tolerability of rotigotine+levodopa (RTG+Ldopa) in Parkinson’s disease (PD) patients aged…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley